Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / SPHRF - COVID-19 Continues But Good Times For mRNA Vaccine Developers Pfizer/BioNTech And Moderna

SPHRF - COVID-19 Continues But Good Times For mRNA Vaccine Developers Pfizer/BioNTech And Moderna

Starpharma Holdings Ltd
  • Pfizer sees $15 billion revenue from the Pfizer/BioNTech COVID vaccine in 2021 and it could completely change Pfizer’s revenue and earnings trajectory. Think about what this will do for BioNTech.
  • The above revenues are for the “pandemic phase.” Pfizer/BioNTech may be considering a 3-4x price increase for their COVID-19 vaccine(s) after this phase. Read this sentence again.
  • Not a lot of progress on treatments, but Viraleze, a convenient nasal spray from Starpharma for prevention/early treatment may complement vaccine programs.

For further details see:

COVID-19 Continues, But Good Times For mRNA Vaccine Developers Pfizer/BioNTech And Moderna
Stock Information
Company Name: Starpharma Holdings Ltd
Stock Symbol: SPHRF
Market: OTC
Website: starpharma.com
Menu
SPHRF SPHRF Quote SPHRF Short SPHRF News SPHRF Articles SPHRF Message Board
Get SPHRF Alerts

News, Short Squeeze, Breakout and More Instantly...